This article is a joke. GLP-1 (glucagon like polpypetide 1) was discovered about 25 years ago. It lowers blood sugar and the human gut secretes it naturally, but it has a short half-life, because it is inactivated by DPP4 (dipeptidyl peptidase 4), another naturally occurring enzyme in the human body. Januvia (by Merck) was the first DPP-4 inhibitor, used to block the DPP-4 enzyme’s degradation of GLP-1, thus lowering blood sugar. Next came a natural mimetic (copy) of GLP-1, Byetta, and it’s analog (synthetic) twin Bydureon, both owned by Astra Zeneca. These drugs came out in the mid 2000’s. Another GLP-1 analog, Victoza (from Novo Nordisk) came out in 2010. There are also a host of Januvia copies on the market (saxagliptin, alogliptin, linogliptin,etc.). Before you start thinking this is a new breakthrough, educate yourselves on the diabetes therapies.
LOL, threatened much?
With all your big words, you think there’s been no progress since the mid-2000’s?
Or is it that you think that research should just stop where it is, because there’s nothing left to discover or develop?
Or, rather, have your employers told you to squelch hope for your 13 coins of silver?
When I see articles that could be of interest to Freepers concerned about diabetes, I post them. My hope is that the information generates discussion with pros and cons, because there is a lot out there about diabetes and not all of it is accurate.
So, I do appreciate your knowledgeable comment... well, except perhaps the snarky last line.